Baxalta Inc. v. Genentech, Inc.

The Federal Circuit affirmed the district court’s ruling that Baxalta’s patent for antibodies that treat Hemophilia A was invalid for lack of enablement and applied the Supreme Court’s 2023 decision in Amgen Inc. v. Sanofi to reach its determination.